AR067568A1 - Agonistas de receptor acoplado a proteina g gpr119 de piridona y una composicion farmaceutica que los contiene - Google Patents
Agonistas de receptor acoplado a proteina g gpr119 de piridona y una composicion farmaceutica que los contieneInfo
- Publication number
- AR067568A1 AR067568A1 ARP080103060A ARP080103060A AR067568A1 AR 067568 A1 AR067568 A1 AR 067568A1 AR P080103060 A ARP080103060 A AR P080103060A AR P080103060 A ARP080103060 A AR P080103060A AR 067568 A1 AR067568 A1 AR 067568A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocyclyl
- cycloalkyl
- aryl
- nr14r14
- alkyl
- Prior art date
Links
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 title abstract 3
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 25
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 24
- 125000003118 aryl group Chemical group 0.000 abstract 23
- 125000000217 alkyl group Chemical group 0.000 abstract 20
- 125000001072 heteroaryl group Chemical group 0.000 abstract 15
- 125000003342 alkenyl group Chemical group 0.000 abstract 14
- 125000000304 alkynyl group Chemical group 0.000 abstract 13
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 12
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 11
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 11
- 125000001475 halogen functional group Chemical group 0.000 abstract 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 7
- 125000001188 haloalkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 -NR2 Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95016207P | 2007-07-17 | 2007-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067568A1 true AR067568A1 (es) | 2009-10-14 |
Family
ID=39864683
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103060A AR067568A1 (es) | 2007-07-17 | 2008-07-16 | Agonistas de receptor acoplado a proteina g gpr119 de piridona y una composicion farmaceutica que los contiene |
| ARP080103061A AR067569A1 (es) | 2007-07-17 | 2008-07-16 | Procedimiento para la modulacion del receptor acoplado a la proteina g gpr 119 y compuestos seleccionados |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103061A AR067569A1 (es) | 2007-07-17 | 2008-07-16 | Procedimiento para la modulacion del receptor acoplado a la proteina g gpr 119 y compuestos seleccionados |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US7928230B2 (enExample) |
| EP (2) | EP2173737B1 (enExample) |
| JP (3) | JP5301539B2 (enExample) |
| KR (2) | KR20100051814A (enExample) |
| CN (3) | CN101801957A (enExample) |
| AR (2) | AR067568A1 (enExample) |
| AT (2) | ATE524460T1 (enExample) |
| AU (2) | AU2008276057B2 (enExample) |
| BR (2) | BRPI0815097A2 (enExample) |
| CA (2) | CA2693444A1 (enExample) |
| CL (2) | CL2008002110A1 (enExample) |
| CO (1) | CO6160315A2 (enExample) |
| CY (2) | CY1112151T1 (enExample) |
| DK (2) | DK2170864T3 (enExample) |
| EA (2) | EA018709B1 (enExample) |
| ES (2) | ES2371515T3 (enExample) |
| HR (2) | HRP20110806T1 (enExample) |
| IL (1) | IL228120A0 (enExample) |
| NZ (2) | NZ582664A (enExample) |
| PE (2) | PE20090449A1 (enExample) |
| PL (2) | PL2170864T3 (enExample) |
| PT (2) | PT2170864E (enExample) |
| SI (2) | SI2170864T1 (enExample) |
| TW (2) | TW200904439A (enExample) |
| WO (2) | WO2009012275A1 (enExample) |
| ZA (2) | ZA201000151B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006059778A1 (ja) * | 2004-12-01 | 2006-06-08 | Banyu Pharmaceutical Co., Ltd. | ē½®ęććŖćć³čŖå°ä½ |
| PE20090222A1 (es) | 2007-05-04 | 2009-03-27 | Bristol Myers Squibb Co | Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119 |
| PL2170864T3 (pl) | 2007-07-17 | 2012-02-29 | Bristol Myers Squibb Co | AgoniÅci receptora gpr119 sprÄżonego z biaÅkiem g - pirydon |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| TW201006821A (en) * | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| MX2011000664A (es) | 2008-07-16 | 2011-02-24 | Schering Corp | Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119. |
| JP2011528369A (ja) * | 2008-07-16 | 2011-11-17 | ć·ć§ć¼ćŖć³ć° ć³ć¼ćć¬ć¤ć·ć§ć³ | äŗē°å¼ćććē°čŖå°ä½ććć³ćććć®ä½æēØę¹ę³ |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| CA2754523A1 (en) * | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| US8481731B2 (en) | 2009-06-24 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| US8293729B2 (en) | 2009-06-24 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ćć¼ćŖć³ć¬ć¼ ć¤ć³ć²ć«ćć¤ć ć¤ć³ćæć¼ćć·ć§ćć« ć²ć¼ć«ć·ć£ćć ććć ćć·ć„ć¬ć³ćÆćć« ćććć³ć° | ē³å°æē åć³é¢é£ē¶ę ć®ę²»ēć§ēØććļ½ļ½ļ½ļ¼ļ¼ļ¼ä½åč¬ćØļ½ļ½ļ½āļ½ļ½é»å®³č¬ćŖćć°ćŖććć³ć®ēµåć |
| US8415367B2 (en) | 2010-04-08 | 2013-04-09 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators |
| EP2566862B1 (en) | 2010-05-06 | 2015-09-16 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| CN102971311B (zh) | 2010-05-06 | 2015-07-08 | ē¾ę¶ē¾ę½č“µå®å ¬åø | ä½äøŗgpr119č°čåēäŗēÆęč³åŗååē© |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| SG188547A1 (en) | 2010-10-08 | 2013-04-30 | Cadila Healthcare Ltd | Novel gpr 119 agonists |
| US9359300B2 (en) | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| DK2648516T3 (da) | 2010-12-06 | 2019-01-02 | Aclaris Therapeutics Inc | Substituerede pyridinon-pyridinylforbindelser |
| WO2012123449A1 (en) * | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim International Gmbh | N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators |
| KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | ė¦¬ģ ķė§ģķ°ģ»¬ģ¤ ģģģė¼ ģė øė | Gpr-119ģ ģ”°ģ ģ ė”ģģ ģ ź·ķ ķķ©ė¬¼ |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9174965B2 (en) | 2012-05-16 | 2015-11-03 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators |
| AU2013290100A1 (en) | 2012-07-11 | 2015-01-29 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| KR102160841B1 (ko) * | 2012-11-13 | 2020-09-28 | ėģ° ź°ź°ģæ ź°ė¶ģķ¤ź°ģ“ģ¤ | 2-ķ¼ė¦¬ė ķķ©ė¬¼ |
| CN102993088A (zh) * | 2012-12-31 | 2013-03-27 | äøåå¤§å¦ | äøē§4-ē¾åŗ-2-å”å¶é ®ēå¶å¤ę¹ę³ |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | ęÆå©ęåå„ēč„åå ¬åø | ē¶å代ļ¼ļ¼ę°®ééē°é”åå ¶ä½ēŗé£ę ¾ē“ åé«čŖæę§åä¹ēØé |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | ē¶å代ä¹åå¶ååē©åå ¶ä½ēŗé£ę ¾ē“ åé«čŖæēÆåä¹ēØé |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | ē¶å代ē7-ę°®ééē°é”åå ¶ä½ēŗé£ę ¾ęæē“ åé«čŖæēÆåä¹ēØé |
| KR102313515B1 (ko) | 2013-06-07 | 2021-10-14 | ģ“ķ“ė¼ė¦¬ģ¤ ģė¼ķØķ±ģ¤, ģøģ½ķ¬ė ģ“ķ°ė | ė©ķø/ķė£Øģ¤ė”-ķ¼ė¦¬ėė-ė©ķ”ģ ģ¹ķė ķ¼ė¦¬ėė ¼-ķ¼ė¦¬ėė ķķ©ė¬¼ ė° ķė£Øģ¤ė”-ķ¼ė¦¬ėÆøėė-ė©ķ”ģ ģ¹ķė ķ¼ė¦¬ėė ¼-ķ¼ė¦¬ėė ķķ©ė¬¼ |
| BR112015031155A2 (pt) | 2013-06-20 | 2017-07-25 | Bayer Cropscience Ag | derivados de sulfureto de arila e derivados de aril sulfĆ³xido como acaricidas e inseticidas |
| EP3010893B1 (de) | 2013-06-20 | 2019-10-02 | Bayer CropScience Aktiengesellschaft | Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide |
| BR112016000241B1 (pt) | 2013-07-08 | 2021-06-22 | Bayer Cropscience Aktiengesellschaft | Compostos pesticidas derivados de sulfeto de arila e sulfĆ³xido de arila, formulaĆ§Ć£o, seus usos, mĆ©todo para controle de pragas e mĆ©todo de proteĆ§Ć£o de semente ou planta |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | ŠŠ½ŃŠµŃŠ¼ŃŃŠ½, ŠŠ½Šŗ. | ŠŃŠ¾ŃŠøŠ²Š¾ŃŠøŠ±ŃŠ¾Š·Š½ŃŠµ ŠæŠøŃŠøŠ“ŠøŠ½Š¾Š½Ń |
| EP2929883A1 (en) | 2014-04-08 | 2015-10-14 | Institut Pasteur | Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors |
| JP6715239B2 (ja) | 2014-09-11 | 2020-07-01 | ć¤ć³ć»ć³ ćć”ć¼ćć·ć„ć¼ćć£ć« ćØćļ¼ćć¼ļ¼ | ē½®ęļ¼āć¢ć¶äŗē°å¼ååē©åć³ćŖć¬ćć·ć³å容ä½čŖæēÆå åćØćć¦ć®ćć®ä½æēØ |
| WO2016130652A1 (en) | 2015-02-10 | 2016-08-18 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 3 |
| JP6578116B2 (ja) * | 2015-03-25 | 2019-09-18 | å ¬ēč²”å£ę³äŗŗēøęØ”äø央åå¦ē ē©¶ę | äøē½®ęļ¼ćć«ćŖćć¢ć«ćć«ļ¼ćØćć¬ć³é”åć³ćć®č£½é ę¹ę³ |
| US10865194B2 (en) | 2017-11-03 | 2020-12-15 | Fondazione Istituto Italiano Di Tecnologia | Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| IL296054A (en) | 2020-03-27 | 2022-10-01 | Aclaris Therapeutics Inc | Oral compositions of mk2 pathway inhibitor for treatment of immune conditions |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| WO2022081573A1 (en) * | 2020-10-12 | 2022-04-21 | University Of Tennessee Research Foundation | Transient receptor potential canonical 3 inhibitors and methods of use thereof |
| CN115504927A (zh) * | 2022-08-15 | 2022-12-23 | å¹æč„æäøå»čÆå¤§å¦ | 4-ē²åŗ-2-åƹē²čÆåŗ-6-ē¾°åŗå”å¶-3-ē²é øåå ¶å¶å¤ę¹ę³åēØé |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3826643A (en) * | 1967-08-07 | 1974-07-30 | American Cyanamid Co | Method of controlling undesirable plant species using 3-nitropyridines |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as Ī²3 agonists |
| US5488064A (en) * | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5491134A (en) * | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid Ī²3 agonist derivatives |
| US5541204A (en) * | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine Ī² 3 adrenergic agonists |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5770615A (en) * | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as Ī²3 agonists |
| US6566384B1 (en) | 1996-08-07 | 2003-05-20 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | ŠŃŠ°Š¹Š·ŠµŃ ŠŃŠ¾Š“Š°ŠŗŃŃ ŠŠ½Šŗ. | Š¤Š°ŃŠ¼Š°ŃŠµŠ²ŃŠøŃŠ½Š° ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøŃŃŃ, ŃŠ¾ Š¼ŃŃŃŠøŃŃ ŃŠ½Š³ŃŠ±ŃŃŠ¾Ń Š°Š»ŃŠ“Š¾Š·Š¾ŃŠµŠ“ŃŠŗŃŠ°Š·Šø ŃŠ° ŃŠ½Š³ŃŠ±ŃŃŠ¾Ń Š³Š»ŃŠŗŠ¾Š³ŠµŠ½ŃŠ¾ŃŃŠ¾ŃŠøŠ»Š°Š·Šø (Š²Š°ŃŃŠ°Š½ŃŠø), ŠŗŠ¾Š¼ŠæŠ»ŠµŠŗŃ, ŃŠŗŠøŠ¹ ŃŃ Š²ŠŗŠ»ŃŃŠ°Ń, ŃŠ° ŃŠæŠ¾ŃŠ¾Š±Šø Š»ŃŠŗŃŠ²Š°Š½Š½Ń ŃŃŠ°Š²ŃŃŠ² Š·Ń ŃŃŠ°Š½Š¾Š¼ ŃŠ½ŃŃŠ»ŃŠ½Š¾ŃŠµŠ·ŠøŃŃŠµŠ½ŃŠ½Š¾ŃŃŃ |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| WO2000038683A1 (en) | 1998-12-23 | 2000-07-06 | Du Pont Pharmaceuticals Company | THROMBIN OR FACTOR Xa INHIBITORS |
| US6586418B2 (en) | 2000-06-29 | 2003-07-01 | Bristol-Myers Squibb Company | Thrombin or factor Xa inhibitors |
| EP1770159A1 (en) | 2000-12-01 | 2007-04-04 | Astellas Pharma Inc. | Process for manufacturing a pharmaceutical composition for treating diabetes |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
| AP1822A (en) * | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| RS20050532A (sr) | 2003-01-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremeÄaja povezanih sa njim, kao Å”to su dijebetes i hiperglikemija |
| DE602004017703D1 (de) | 2003-02-24 | 2008-12-24 | Arena Pharm Inc | Phenyl- und pyridylpiperidinderivate als modulatoren des glucose-metabolismus |
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| US7003597B2 (en) * | 2003-07-09 | 2006-02-21 | International Business Machines Corporation | Dynamic reallocation of data stored in buffers based on packet size |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| UA86943C2 (ru) * | 2003-07-11 | 2009-06-10 | ŠŃŠµŠ½Š° Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š·, ŠŠ½Šŗ. | Š¢ŃŠøŠ·Š°Š¼ŠµŃŠµŠ½Š½ŃŠµ ŠæŃŠ¾ŠøŠ·Š²Š¾Š“Š½ŃŠµ Š°ŃŠøŠ»Š¾Š² Šø Š³ŠµŃŠµŃŠ¾Š°ŃŠøŠ»Š¾Š² ŠŗŠ°Šŗ Š¼Š¾Š“ŃŠ»ŃŃŠ¾ŃŃ Š¼ŠµŃŠ°Š±Š¾Š»ŠøŠ·Š¼Š° Šø ŠæŃŠ¾ŃŠøŠ»Š°ŠŗŃŠøŠŗŠ° Šø Š»ŠµŃŠµŠ½ŠøŠµ ŃŠ²ŃŠ·Š°Š½Š½ŃŃ Ń Š½ŠøŠ¼Šø Š½Š°ŃŃŃŠµŠ½ŠøŠ¹ |
| KR20060056944A (ko) * | 2003-07-14 | 2006-05-25 | ģė ė ķė§ģķ°ģ¹¼ģ¤, ģøķ¬. | ėģ¬ ģ”°ģ ģ ė”ģ ģµķ©ė ģė¦“ ė° ķ¤ķ ė”ģė¦“ ģ ėģ²“ ė°ģ“ģ ź“ė Øė ģ„ģ ģ ģė°© ėė ģ¹ė£ |
| US20070088163A1 (en) | 2003-09-12 | 2007-04-19 | Kemia, Inc. | Modulators of calcitonin and amylin activity |
| US7732456B2 (en) * | 2004-03-05 | 2010-06-08 | Banyu Pharmaceutical Co., Ltd. | Pyridone derivative |
| DK2060266T3 (da) | 2004-03-17 | 2011-11-14 | 7Tm Pharma As | Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb |
| MXPA06012683A (es) * | 2004-05-03 | 2007-01-16 | Hoffmann La Roche | Derivados de indolilo como moduladores de receptor x del higado. |
| EA011671B1 (ru) | 2004-06-04 | 2009-04-28 | ŠŃŠµŠ½Š° Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š»Š·, ŠŠ½Šŗ. | ŠŠ°Š¼ŠµŃŠµŠ½Š½ŃŠµ ŠæŃŠ¾ŠøŠ·Š²Š¾Š“Š½ŃŠµ Š°ŃŠøŠ»Š° Šø Š³ŠµŃŠµŃŠ¾Š°ŃŠøŠ»Š° Š² ŠŗŠ°ŃŠµŃŃŠ²Šµ Š¼Š¾Š“ŃŠ»ŃŃŠ¾ŃŠ¾Š² Š¼ŠµŃŠ°Š±Š¾Š»ŠøŠ·Š¼Š° Šø Š“Š»Ń ŠæŃŠ¾ŃŠøŠ»Š°ŠŗŃŠøŠŗŠø Šø Š»ŠµŃŠµŠ½ŠøŃ ŃŠ²ŃŠ·Š°Š½Š½ŃŃ Ń Š½ŠøŠ¼ ŃŠ°ŃŃŃŃŠ¾Š¹ŃŃŠ² |
| EP1838706A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor agonists |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| CA2612187C (en) * | 2005-06-23 | 2013-05-07 | Emory University | Stereoselective synthesis of amino acid analogs for tumor imaging |
| JP2008545008A (ja) | 2005-06-30 | 2008-12-11 | ććć·ćć£ćŖć³ć»ćŖćććć | ļ¼§ļ½ļ½ļ½ć¢ć“ćć¹ć |
| US20090325924A1 (en) * | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| EP2152707B1 (en) * | 2007-05-04 | 2012-06-20 | Bristol-Myers Squibb Company | [6,5]-bicyclic gpr119 g protein-coupled receptor agonists |
| PE20090222A1 (es) * | 2007-05-04 | 2009-03-27 | Bristol Myers Squibb Co | Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119 |
| PL2170864T3 (pl) * | 2007-07-17 | 2012-02-29 | Bristol Myers Squibb Co | AgoniÅci receptora gpr119 sprÄżonego z biaÅkiem g - pirydon |
-
2008
- 2008-07-16 PL PL08781867T patent/PL2170864T3/pl unknown
- 2008-07-16 CA CA2693444A patent/CA2693444A1/en not_active Abandoned
- 2008-07-16 AT AT08781867T patent/ATE524460T1/de active
- 2008-07-16 AU AU2008276057A patent/AU2008276057B2/en not_active Ceased
- 2008-07-16 BR BRPI0815097A patent/BRPI0815097A2/pt not_active IP Right Cessation
- 2008-07-16 KR KR1020107003333A patent/KR20100051814A/ko not_active Withdrawn
- 2008-07-16 CN CN200880108168A patent/CN101801957A/zh active Pending
- 2008-07-16 AR ARP080103060A patent/AR067568A1/es unknown
- 2008-07-16 US US12/173,864 patent/US7928230B2/en active Active
- 2008-07-16 TW TW097127045A patent/TW200904439A/zh unknown
- 2008-07-16 EP EP08781868A patent/EP2173737B1/en not_active Not-in-force
- 2008-07-16 DK DK08781867.0T patent/DK2170864T3/da active
- 2008-07-16 AT AT08781868T patent/ATE540945T1/de active
- 2008-07-16 CN CN2008801081672A patent/CN101801956B/zh not_active Expired - Fee Related
- 2008-07-16 BR BRPI0814428-1A2A patent/BRPI0814428A2/pt not_active IP Right Cessation
- 2008-07-16 PE PE2008001197A patent/PE20090449A1/es not_active Application Discontinuation
- 2008-07-16 EA EA201000210A patent/EA018709B1/ru not_active IP Right Cessation
- 2008-07-16 CA CA2693439A patent/CA2693439A1/en not_active Abandoned
- 2008-07-16 PL PL08781868T patent/PL2173737T3/pl unknown
- 2008-07-16 SI SI200830464T patent/SI2170864T1/sl unknown
- 2008-07-16 KR KR1020107003332A patent/KR20100045471A/ko not_active Withdrawn
- 2008-07-16 WO PCT/US2008/070101 patent/WO2009012275A1/en not_active Ceased
- 2008-07-16 TW TW097127046A patent/TW200904440A/zh unknown
- 2008-07-16 EP EP08781867A patent/EP2170864B1/en not_active Not-in-force
- 2008-07-16 US US12/173,856 patent/US8003796B2/en active Active
- 2008-07-16 JP JP2010517123A patent/JP5301539B2/ja not_active Expired - Fee Related
- 2008-07-16 WO PCT/US2008/070103 patent/WO2009012277A1/en not_active Ceased
- 2008-07-16 HR HR20110806T patent/HRP20110806T1/hr unknown
- 2008-07-16 EA EA201000211A patent/EA016595B1/ru not_active IP Right Cessation
- 2008-07-16 ES ES08781867T patent/ES2371515T3/es active Active
- 2008-07-16 PT PT08781867T patent/PT2170864E/pt unknown
- 2008-07-16 NZ NZ582664A patent/NZ582664A/en not_active IP Right Cessation
- 2008-07-16 SI SI200830592T patent/SI2173737T1/sl unknown
- 2008-07-16 AR ARP080103061A patent/AR067569A1/es not_active Application Discontinuation
- 2008-07-16 DK DK08781868.8T patent/DK2173737T3/da active
- 2008-07-16 JP JP2010517122A patent/JP5318867B2/ja not_active Expired - Fee Related
- 2008-07-16 ES ES08781868T patent/ES2378914T3/es active Active
- 2008-07-16 PE PE2008001196A patent/PE20090888A1/es not_active Application Discontinuation
- 2008-07-16 PT PT08781868T patent/PT2173737E/pt unknown
- 2008-07-16 HR HR20120221T patent/HRP20120221T1/hr unknown
- 2008-07-16 AU AU2008276055A patent/AU2008276055B2/en not_active Ceased
- 2008-07-16 NZ NZ582661A patent/NZ582661A/en not_active IP Right Cessation
- 2008-07-16 CN CN201310495045.6A patent/CN103550218A/zh active Pending
- 2008-07-17 CL CL200802110A patent/CL2008002110A1/es unknown
- 2008-07-17 CL CL200802111A patent/CL2008002111A1/es unknown
-
2010
- 2010-01-08 ZA ZA2010/00151A patent/ZA201000151B/en unknown
- 2010-01-15 ZA ZA2010/00326A patent/ZA201000326B/en unknown
- 2010-01-15 CO CO10003756A patent/CO6160315A2/es unknown
-
2011
- 2011-03-07 US US13/041,564 patent/US8178561B2/en active Active
- 2011-06-14 US US13/159,497 patent/US8232404B2/en active Active
- 2011-12-14 CY CY20111101241T patent/CY1112151T1/el unknown
-
2012
- 2012-04-09 CY CY20121100343T patent/CY1112751T1/el unknown
- 2012-04-24 US US13/454,789 patent/US20120232048A1/en not_active Abandoned
- 2012-06-12 US US13/494,489 patent/US8513424B2/en active Active
-
2013
- 2013-07-10 JP JP2013144778A patent/JP2013237680A/ja not_active Withdrawn
- 2013-08-26 IL IL228120A patent/IL228120A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2371515T3 (es) | Agonistas del receptor grp119 acoplado a proteĆna g. piridona. | |
| AR066437A1 (es) | Benzo-oxazinas y pirimidinas condensadas con heterociclos que contienen nitrogeno y oxigeno, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de diabetes,obesidad y enfermedades asociadas a ellas. | |
| AR066438A1 (es) | Compuestos nitrogenados condensados, composiciones farmaceuticas que los contienen y usos de las mismas para el tratamiento de diabetes, obesidad y enfermedades asociadas a ellas. | |
| AR073254A1 (es) | Analogos de piridona y piridazona como moduladores de gpr119 | |
| AR066348A1 (es) | Inhibidores de las iap | |
| PE20221006A1 (es) | Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae" | |
| AR058700A1 (es) | Compuestos heterociclicos como bloqueadores del canal de sodio epitelial | |
| AR065266A1 (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal | |
| MX2020000261A (es) | Nuevos compuestos. | |
| AR054320A1 (es) | Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas | |
| AR054789A1 (es) | Antagonistas del receptor 1 de triazolopiridina canabinoide | |
| AR104174A1 (es) | Oxadiazoles sustituidos con deuterio | |
| CO6210724A2 (es) | Compuesto heterociclico y composicion farmaceutica del mismo | |
| PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
| AR083161A1 (es) | Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, composiciones farmaceuticas que los comprenden, su uso en medicamentos, intermediarios de su sintesis y metodos de preparacion de los mismos | |
| AR074648A1 (es) | Derivados de isoxazolina que poseen un anillo de cuatro miembros como grupo terminal, intermediarios de sintesis, composiciones biocidas que los contienen y metodos para combatir y controlar dichas plagas | |
| PE20142400A1 (es) | Compuestos novedosos | |
| CO6180430A2 (es) | Analogos tiofeno para el tratamiento o prevencion de infecciones por flavivirus | |
| PE20071022A1 (es) | Compuestos derivados de dibencilamina como inhibidores de la proteina de transferencia del colesteril ester (cept) | |
| ATE370982T1 (de) | Polypropylen-blasfolie | |
| CO6241113A2 (es) | Inhibidores del receptor de quimioquinas cx cr 3 | |
| AR070274A1 (es) | Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| PE20161239A1 (es) | Compuesto de ciclopenteno y ciclopentadieno para controlar plagas de invertebrados | |
| AR070273A1 (es) | Derivados de heteroarilamida diazepinopirimidinona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| AR053228A1 (es) | Derivados de azol en calidad de inibidores de lipasas y fosfolipasas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |